Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry Study.

ABSTRACT:

Purpose

To examine the impact of obesity on treatment outcomes in inflammatory bowel disease (IBD).

Methods

Patients aged ≥ 16 years, with IBD, a documented baseline body mass index (BMI), and starting thiopurines and allopurinol, intravenous (iv) vedolizumab, subcutaneous (sc) vedolizumab, ustekinumab, ozanimod, filgotinib, or tofacitinib were selected from the Dutch Initiative on Crohn and Colitis (ICC) registry. Underweight patients (BMI < 18.5 mg/kg²) were excluded. The primary outcome was steroid-free clinical remission (i.e. Simple Clinical Colitis Activity Index (SCCAI) ≤ 2 for ulcerative colitis (UC) and IBD-unclassified (IBD-U), and Harvey Bradshaw Index (HBI) < 5 for Crohn's disease (CD)) at week 24. Remission rates were compared between normal weight (B

SUBMITTER: Oomkens D 

PROVIDER: S-EPMC12367900 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature